New insider activity at Abeona Therapeutics ( (ABEO) ) has taken place on October 1, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Abeona Therapeutics stock, CFO Joseph Walter Vazzano sold 9,035 shares, amounting to $48,698. SVP and CLO Brendan M. O’Malley parted with 9,366 shares, totaling $50,482. Meanwhile, CEO Vishwas Seshadri sold 19,274 shares, with a total value of $103,886.
Spark’s Take on ABEO Stock
According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.
Abeona Therapeutics faces substantial financial challenges with no current revenue and ongoing losses, impacting its overall score. However, the promising potential for FDA approvals and significant revenue opportunities from new therapies provide a positive outlook. Despite bullish technical signals, the high RSI suggests caution. The stock’s valuation remains unattractive due to its negative P/E ratio, but strong earnings call projections and adequate cash reserves offer some optimism for future performance.
To see Spark’s full report on ABEO stock, click here.
More about Abeona Therapeutics
YTD Price Performance: -10.66%
Average Trading Volume: 784,533
Technical Sentiment Signal: Sell
Current Market Cap: $273.3M